Cathepsin S EC 3.4.22.27-Pipeline Review, H1 2016

Cathepsin S EC 3.4.22.27-Pipeline Review, H1 2016


  • Products Id :- GMDHC0111TDB
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cathepsin S (EC 3.4.22.27)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Cathepsin S (EC 3.4.22.27)-Pipeline Review, H1 2016', provides in depth analysis on Cathepsin S (EC 3.4.22.27) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin S (EC 3.4.22.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin S (EC 3.4.22.27) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Cathepsin S (EC 3.4.22.27)

The report reviews Cathepsin S (EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cathepsin S (EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects

The report assesses Cathepsin S (EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cathepsin S (EC 3.4.22.27) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cathepsin S (EC 3.4.22.27)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cathepsin S (EC 3.4.22.27) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Cathepsin S (EC 3.4.22.27) Overview 6

Therapeutics Development 7

Cathepsin S (EC 3.4.22.27)-Products under Development by Stage of Development 7

Cathepsin S (EC 3.4.22.27)-Products under Development by Therapy Area 8

Cathepsin S (EC 3.4.22.27)-Products under Development by Indication 9

Cathepsin S (EC 3.4.22.27)-Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Cathepsin S (EC 3.4.22.27)-Products under Development by Companies 12

Cathepsin S (EC 3.4.22.27)-Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 17

Cathepsin S (EC 3.4.22.27)-Companies Involved in Therapeutics Development 19

Amura Holdings Limited 19

F. Hoffmann-La Roche Ltd. 20

Fusion Antibodies Limited 21

LEO Pharma A/S 22

Virobay Inc. 23

Cathepsin S (EC 3.4.22.27)-Drug Profiles 24

AM-3840-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

AM-3876-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Fsn-0503h-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

RG-7625-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

RO-5461111-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

VBY-036-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

VBY-129-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

VBY-285-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

VBY-50365-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

VBY-825-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

VBY-891-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Cathepsin S (EC 3.4.22.27)-Dormant Projects 36

Cathepsin S (EC 3.4.22.27)-Discontinued Products 37

Cathepsin S (EC 3.4.22.27)-Featured News & Press Releases 38

Nov 14, 2014: Virobay To Present Data On Two Cathepsin S Inhibitor Programs In Neuropathic Pain And Alzheimer's Disease At The 2014 Society For Neuroscience Annual Meeting 38

May 23, 2013: Virobay Initiates Phase I Trial Of VBY-036 For Treatment Of Neuropathic Pain 38

Mar 18, 2013: Virobay And LEO Pharma Initiate Phase I Trial Of VBY-891 For Oral Treatment Of Psoriasis 39

Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Figures

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of Products under Development by Top 10 Indication, H1 2016 9

Comparative Analysis by Early Stage Products, H1 2016 11

Assessment by Monotherapy/Combination Products, H1 2016 14

Number of Products by Stage and Mechanism of Actions, H1 2016 15

Number of Products by Stage and Routes of Administration, H1 2016 16

Number of Products by Molecule Types, H1 2016 17

Number of Products by Stage and Molecule Type, H1 2016 17

List of Tables

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of Products under Development by Indication, H1 2016 9

Comparative Analysis by Late Stage Development, H1 2016 10

Comparative Analysis by Early Stage Products, H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Products under Development by Companies, H1 2016 13

Assessment by Monotherapy/Combination Products, H1 2016 14

Number of Products by Stage and Mechanism of Action, H1 2016 15

Number of Products by Stage and Route of Administration, H1 2016 16

Number of Products by Stage and Molecule Type, H1 2016 18

Pipeline by Amura Holdings Limited, H1 2016 19

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 20

Pipeline by Fusion Antibodies Limited, H1 2016 21

Pipeline by LEO Pharma A/S, H1 2016 22

Pipeline by Virobay Inc., H1 2016 23

Dormant Projects, H1 2016 36

Discontinued Products, H1 2016 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amura Holdings Limited

F. Hoffmann-La Roche Ltd.

Fusion Antibodies Limited

LEO Pharma A/S

Virobay Inc.

Cathepsin S (EC 3.4.22.27) Therapeutic Products under Development, Key Players in Cathepsin S (EC 3.4.22.27) Therapeutics, Cathepsin S (EC 3.4.22.27) Pipeline Overview, Cathepsin S (EC 3.4.22.27) Pipeline, Cathepsin S (EC 3.4.22.27) Pipeline Assessment

select a license

Single User License
USD 3500 INR 224280
Site License
USD 7000 INR 448560
Corporate User License
USD 10500 INR 672840

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com